Vaccination A phase 2 study of a CMV-vaccine published in 2009 indicated an efficacy of<unk> 0%—the protection provided was limited, and a number of subjects contracted CMV infection despite vaccination. In one case also congenital CMV was encountered. In 2013, Astellas Pharma started on individuals who received a hematopoietic stem cell transplant a phase 3 trial with its CMV deoxyribonucleic acid DNA cytomegalovirus vaccine ASP0113. In 2015, Astellas Pharma commenced on healthy volunteers a phase 1 trial with its cytomegalovirus vaccine ASP0113. Further cytomegalovirus vaccines candidates are the CMV-MVA Triplex vaccine and the CMVpp65-A*0201 peptide vaccine. Both vaccine candidates are sponsored by the City of Hope National Medical Center. As of 2016, the development is in clinical phase 2 trial stage. Hygiene The Centers for Disease Control and Prevention (CDC) recommend regular hand washing, especially after changing diapers. Hand washing is also recommended after feeding a child, wiping a child's nose or mouth, or handling children's toys.
Human betaherpesvirus 5
Human betaherpesvirus 7
Human herpesvirus 6
Trichodysplasia spinulosa polyomavirus
Human T-lymphotropic virus
Oncolytic adenovirus
Human T-lymphotropic virus 1
Yaba monkey tumor virus